Business Value: sonnetbio.com (SONN)

Graphic logo of sonnetbio.com (SONN)

Sonnet BioTherapeutics (SONN) relies on patent protection for unique protein modification methods, guaranteeing its leadership status in high-cost medical niches. The business focuses on R&D development and the creation of extended-release drug delivery systems for combating tumors. The current market quotes illustrated below, with an Enterprise Value of 8.67, confirm growth potential driven by successful clinical trials and future contracts with pharma behemoths.

Sonnet BioTherapeutics Holdings (SONN) - Total Company Value from 11/23/2025 to 12/13/2025

Sonnet BioTherapeutics Holdings (SONN) - metric breakdowns and financial figures

- market value and analyst target forecast:
Market Price Sonnet BioTherapeutics Holdings, Inc.|SONN - Price Target Chart
- company stock exchange capitalization indicators:
Market Capitalization Sonnet BioTherapeutics|SONN - Total Company Value
- balance sheet net asset value indicators:
Equity per Share Sonnet BioTherapeutics|SONN - Company Book Value|Market-to-Book Ratio sonnetbio.com|SONN - Aggregate Company Assets
- debt level and financial liquidity data:
Debt to Equity Ratio Sonnet BioTherapeutics|SONN - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Sonnet BioTherapeutics Holdings, Inc.|SONN - Company Debts|Debts to Book Value Sonnet BioTherapeutics|SONN - Company Long-Term Debt|Company Short-Term Debt Sonnet BioTherapeutics|Immediate Liquidity sonnetbio.com
- earnings and valuation multiples indicators:
SONN - Net Profit
Analysis of all company metrics:Sonnet BioTherapeutics
Flagship merchandise of Sonnet BioTherapeutics Holdings Inc.

Enterprise value determines the actual buyout price of a business, accounting for debt load and liquid assets. The formula sums market capitalization with liabilities, subtracting cash to identify the net financial leverage. The trend of total capitalization including debt reflects the company's sensitivity to market cycles. For Sonnet BioTherapeutics (SONN), this indicator is critical due to high R&D expenditures. Investments in the FHAB platform directly impact asset value.

Competitors of Sonnet BioTherapeutics (SONN)

ImmunityBio Inc (IBRX) - Total Enterprise Value|IMCR - Total Company Value|JANX (Janux Corp) - Business Value|Arcus Biosciences, Inc. (RCUS) - Total Company Value|Business Value ZYME|Total Company Value Tango Therapeutics, Inc.|Total Enterprise Value Iovance Biotherapeutics Inc IOVA|Total Company Value Immatics Corp (IMTX)|Xencor Inc. - Business Value|Enterprise Value CMPX (Compass Therapeutics)|REPL - Real Price to Acquire Entire Company|LYEL - Total Company Value|Total Enterprise Value Innate Pharma SA|pyxisoncology.com (PYXS) - Total Company Value|CGEN (Compugen) - Total Company Value|Total Company Value IO Biotech, Inc.|Total Enterprise Value sutrobio.com STRO|Enterprise Value INKT|werewolftx.com (HOWL) - Full Takeover Company Value|Immix Biopharma - Real Price to Acquire Entire Company|ALX Oncology Holdings Inc. (ALXO) - Total Enterprise Value|CUE: Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash PDSB (PDS Biotechnology)|MAIA: Enterprise Value|LIMN - Company Buyout Price|Total Company Value LAVA Therapeutics NV|Real Price to Acquire Entire Company NextCure Corporation (NXTC)|Total Company Value Leap Therapeutics, Inc. (LPTX)|Real Price to Acquire Entire Company intensitytherapeutics.com INTS|Sensei Biotherapeutics, Inc. - Real Price to Acquire Entire Company|Enterprise Value Theriva Biologics Inc TOVX|GRTS - Total Company Value|KA (Kineta Corp) - Business Value|NexImmune, Inc. (NEXI) - Total Company Value|Total Enterprise Value Turnstone Biologics Corp. (TSBX)|Real Price to Acquire Entire Company VCNX|HARP - Full Takeover Company Value